These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Progress in the therapy of myelodysplastic syndromes. Boogaerts MA Blut; 1989 Jun; 58(6):265-70. PubMed ID: 2472183 [TBL] [Abstract][Full Text] [Related]
7. An update on the treatment of myelodysplastic syndromes. Kurtin SE; Demakos EP Clin J Oncol Nurs; 2010 Jun; 14(3):E29-44. PubMed ID: 20529786 [TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. Odenike O; Onida F; Padron E Am Soc Clin Oncol Educ Book; 2015; ():e398-412. PubMed ID: 25993202 [TBL] [Abstract][Full Text] [Related]
9. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Ganser A; Karthaus M Leuk Lymphoma; 1997 Dec; 26 Suppl 1():13-27. PubMed ID: 9570676 [TBL] [Abstract][Full Text] [Related]
10. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia. Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271 [TBL] [Abstract][Full Text] [Related]
11. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases]. Guan M; Chen SC; Ge CW Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296 [TBL] [Abstract][Full Text] [Related]
12. [Clinical application of retinoic acid and vitamin D3 derivatives to the treatment of refractory anemias]. Yoshida Y Nihon Rinsho; 1993 Apr; 51(4):1023-8. PubMed ID: 8387118 [TBL] [Abstract][Full Text] [Related]
13. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020 [TBL] [Abstract][Full Text] [Related]
14. [Therapeutic possibilities in the treatment of the myelodysplasia syndrome]. Bozóky G; Biliczki F Orv Hetil; 1991 May; 132(19):1011-5. PubMed ID: 2027674 [TBL] [Abstract][Full Text] [Related]
15. A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients. Yu ZP; Ding JH; Sun AN; Ge Z; Chen BA; Wu DP Stem Cells Dev; 2017 Aug; 26(15):1132-1139. PubMed ID: 28494646 [TBL] [Abstract][Full Text] [Related]
17. Advances in supportive care of myelodysplastic syndromes. Gordon MS Semin Hematol; 1999 Oct; 36(4 Suppl 6):21-4. PubMed ID: 10530713 [TBL] [Abstract][Full Text] [Related]
18. [Myelodysplastic syndromes--an overview for the practitioner]. Solenthaler M; Tobler A Ther Umsch; 2004 Feb; 61(2):117-24. PubMed ID: 15018394 [TBL] [Abstract][Full Text] [Related]
19. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S; Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903 [TBL] [Abstract][Full Text] [Related]